Donor-derived cell-free DNA (dd-cfDNA): an emerging biomarker of allograft health in single solid organ transplant recipients.

CareDx has developed AlloSure, a proprietary analytically validated next-generation sequencing (NGS) test that measures the percent of donor-derived cell-free DNA (dd-cfDNA) in single solid organ transplant recipients.


AlloSure measures the percent of transplanted donor-derived cell-free DNA from the total cell-free DNA present from blood in single solid organ transplant recipients.

AlloSure quantifies dd-cfDNA in transplant recipients without prior knowledge of the donor or recipient genotype.

Additional research is currently underway to further characterize the performance in AlloSure in both renal and cardiac transplant patients.

AlloSure is now available for order through CareDx.

Proposals for scientific collaborations on AlloSure and dd-cfDNA are welcomed.

For further information, or to order AlloSure, please contact CareDx: (888) 255-6627 or

Additional Information:

AlloSure press release.


Donor-derived Cell-free DNA in Plasma Increases with Rejection and Decreases after Treatment in Kidney Transplant Recipients


Proficiency Testing for and Surveillance of Heart Transplant Health Using Donor-Derived Cell-Free DNA

AlloSure is not available for testing samples that originate in the State of New York.